General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Boehringer Ingelheim(SIGNIFICANT), Pfizer(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), AbbVie, Inc.(MODEST), Bayer(MODEST), Medscape(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Medtronic Inc(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Roche(MODEST), Janssen(SIGNIFICANT), CeleCor(SIGNIFICANT), Phillips(MODEST), Abiomed(MODEST), Alnylam Pharm.(MODEST), Anthos Therapuetic, LLC(MODEST), HengRui(MODEST), Cardionomic(SIGNIFICANT), Boston Scientific(SIGNIFICANT), REATA(MODEST), NephroSynergy(SIGNIFICANT), Veralox Therapeutics, Inc. (MODEST) EQUITY INTERESTS/STOCK OPTIONS: Tenac.io(MODEST) RESEARCH/RESEARCH GRANTS: Boehringer Ingelheim(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), Pfizer(SIGNIFICANT), Janssen Pharmaceuticals(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), FDA(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), NIH(SIGNIFICANT), Lilly(SIGNIFICANT), Philips(SIGNIFICANT), Alnylam(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Roche(SIGNIFICANT)

View Full Disclosure